FluGen was founded in response to the need for significant improvement in vaccine efficacy, most notably with influenza vaccines. Current influenza vaccines work less than half the time in most years even in healthy adults. FluGen’s response to this problem is the development of a single replication influenza vaccine, M2SR, which provides protection without generating the symptoms caused by replication of the virus. This M2SR vaccine or REDEE FLU as it is known has shown the ability to prevent infection even with mismatched viral strains. REDEE FLU is anticipated to enter human clinical trials in 2016.